Cytotoxic Therapy Provides a Fitness Advantage to Rare HSPCs Harboring Somatic TP53 Mutations.

被引：0

作者：

Wong, T. N. ^{[1
]}

Ramsingh, G. ^{[2
]}

Young, A. L. ^{[6
]}

Klco, J. M. ^{[3
]}

Miller, C. A. ^{[5
]}

Petti, A. ^{[5
]}

Demeter, R. ^{[5
]}

Welch, J. S. ^{[1
]}

Helton, N. M. ^{[1
]}

Li, T. ^{[5
]}

Lamprecht, T. L. ^{[3
]}

Fulton, R. S. ^{[5
]}

Heath, S. ^{[1
]}

Ding, L. ^{[5
]}

Mardis, E. R. ^{[5
]}

Westervelt, P. ^{[1
]}

DiPersio, J. F. ^{[1
]}

Walter, M. J. ^{[1
]}

Graubert, T. A. ^{[4
]}

Ley, T. J. ^{[1
]}

Wilson, R. K. ^{[5
]}

Druley, T. E. ^{[5
,6
]}

Link, D. C. ^{[1
]}

机构：

[1] Washington Univ, Dept Med, St Louis, MO USA

[2] USC, Los Angeles, CA USA

[3] St Jude Childrens Res Hosp, Memphis, TN 38105 USA

[4] Massachusetts Gen Hosp, Boston, MA 02114 USA

[5] Washington Univ, McDonnell Genome Inst, St Louis, MO USA

[6] Washington Univ, Dept Pediat, St Louis, MO 63130 USA

来源：

ENVIRONMENTAL AND MOLECULAR MUTAGENESIS | 2016年 / 57卷

关键词：

D O I：

暂无

中图分类号：

X [环境科学、安全科学];

学科分类号：

08 ; 0830 ;

摘要：

S59

引用

页码：S54 / S54

页数：1

共 50 条

[1] Universal Poor Survival in Children With Medulloblastoma Harboring Somatic TP53 Mutations
Tabori, Uri
Baskin, Berivan
Shago, Mary
Alon, Noa
Taylor, Michael D.
Ray, Peter N.
Bouffet, Eric
Malkin, David
Hawkins, Cynthia
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) : 1345 - 1350
[2] UNIVERSAL POOR SURVIVAL IN CHILDREN WITH MEDULLOBLASTOMA HARBORING SOMATIC TP53 MUTATIONS
Tabori, Uri
Zhukova, Nataliya
Baskin, Berivan
Taylor, Michael D.
Bouffet, Eric
Ray, Peter
Alon, Noa
Malkin, David
Hawkins, Cynthia
[J]. NEURO-ONCOLOGY, 2009, 11 (05) : 652 - 652
[3] Differential responses to therapy in Hispanic NSCLC patients with EGFR, KRAS, or TP53 mutations.
Basher, Fahmin
Saravia, Diana
Lopes, Gilberto
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[4] Immunohistochemical correlates of TP53 somatic mutations in cancer
Murnyak, Balazs
Hortobagyi, Tibor
[J]. ONCOTARGET, 2016, 7 (40) : 64910 - 64920
[5] Somatic TP53 Mutations in the Era of Genome Sequencing
Hainaut, Pierre
Pfeifer, Gerd P.
[J]. COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2016, 6 (11):
[6] Histopathological features of breast cancers in women with germline TP53 mutations.
Masciari, S.
Kandel, M.
Digianni, L.
Dillon, D.
Li, F.
Garber, J.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 548S - 548S
[7] A phase I trial of pazopanib and vorinostat: The role of TP53 mutations.
Hou, Ming-Mou
Bellido, Jorge
Naing, Aung
Falchook, Gerald Steven
Hess, Kenneth R.
Zinner, Ralph
Wheler, Jennifer J.
Subbiah, Vivek
Hong, David S.
Piha-Paul, Salina Anne
Tsimberidou, Apostolia Maria
Karp, Daniel D.
Kurzrock, Razelle
Meric-Bernstam, Funda
Fu, Siqing
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[8] Concurrent somatic alterations of TP53 and RB1 in Chinese lung adenocarcinoma with or without EGFR mutations.
Wang, Jun
Chen, Gang
Zhang, Bicheng
Sun, Jianguo
Liang, Jing
Liu, Xiaolin
Li, Yan
Wang, Baocheng
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[9] Durable remissions following combined targeted therapy in patients with CLL harboring TP53 deletions and/or mutations
Cramer, Paula
Tausch, Eugen
von Tresckow, Julia
Giza, Adam
Robrecht, Sandra
Schneider, Christof
Furstenau, Moritz
Langerbeins, Petra
Al-Sawaf, Othman
Pelzer, Benedikt W.
Fink, Anna Maria
Fischer, Kirsten
Wendtner, Clemens-Martin
Eichhorst, Barbara
Kneba, Michael
Stilgenbauer, Stephan
Hallek, Michael
[J]. BLOOD, 2021, 138 (19) : 1805 - 1816
[10] TP53 mutations in MCL: more therapy is not better
Cohen, Jonathon B.
[J]. BLOOD, 2017, 130 (17) : 1876 - 1877

← 1 2 3 4 5 →